Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.

Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO

The Journal of clinical endocrinology and metabolism1 Dec 1996Cited by 158 (Europe PMC)

PMID8954023DOI10.1210/jcem.81.12.8954023PepBankPUB-08954023

Source link PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In healthy older adults, 2 weeks of MK‑677 increased GH concentrations in a dose-dependent manner, with 25 mg/day increasing mean 24-h GH by 97% versus baseline.
In plain wordsIn healthy older adults, 2 weeks of daily MK‑677 raised growth hormone more at higher doses, with a 97% rise at 25 mg/day versus baseline.
Peptide
MK-677 (ibutamoren)
Outcome
Increase24-h mean GH concentration
Study
n: not reported in source
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2, 10 or 25 mg/day · oral · 2 weeksAs given in this study (human).
Measurements
GH increase
97%
25 mg/day
SE of mean 24-h GH concentration increase
23%
25 mg/day MK-677, 2 weeks versus baseline
P value for mean 24-h GH concentration increase
< 0.05 unitless
25 mg/day MK-677, 2 weeks versus baseline
Source sentences
Summary
MK-677 administration for 2 weeks increased GH concentrations in a dose-dependent manner, with 25 mg/day increasing mean 24-h GH concentration 97 +/- 23% (mean +/- SE; P < 0.05 vs. baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial.
Summary · context
They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days.
Report a problemFND-0895402302
02HumanRandomized controlled trialEfficacy outcome
In healthy older adults, MK‑677 enhanced preexisting pulsatile GH secretion.
In plain wordsIn healthy older adults, MK‑677 enhanced existing pulses of GH release.
Peptide
MK-677 (ibutamoren)
Outcome
IncreasePulsatile GH secretion
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
This increase was due to an enhancement of preexisting pulsatile GH secretion.
3 context sentences(design, population, supporting numbers)
Summary · context
MK-677 administration for 2 weeks increased GH concentrations in a dose-dependent manner, with 25 mg/day increasing mean 24-h GH concentration 97 +/- 23% (mean +/- SE; P < 0.05 vs. baseline).
Summary · context
Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial.
Summary · context
They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days.
Report a problemFND-0895402303
03HumanRandomized controlled trialEfficacy outcome
In healthy older adults, MK‑677 increased GH pulse height.
In plain wordsIn healthy older adults, GH pulse height increased with MK‑677.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseGH pulse height
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
GH pulse height and interpulse nadir concentrations increased significantly without significant changes in the number of pulses.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial.
Summary · context
They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days.
Report a problemFND-0895402304
04HumanRandomized controlled trialEfficacy outcome
In healthy older adults, MK‑677 increased interpulse GH nadir concentrations.
In plain wordsIn healthy older adults, GH levels between pulses increased with MK‑677.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseInterpulse GH nadir
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
GH pulse height and interpulse nadir concentrations increased significantly without significant changes in the number of pulses.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial.
Summary · context
They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days.
Report a problemFND-0895402305
05HumanRandomized controlled trialEfficacy outcome
In healthy older adults, MK‑677 did not significantly change the number of GH pulses.
In plain wordsIn healthy older adults, MK‑677 did not significantly change the number of GH pulses.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeNumber of GH pulses
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
GH pulse height and interpulse nadir concentrations increased significantly without significant changes in the number of pulses.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial.
Summary · context
They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days.
Report a problemFND-0895402306
06HumanRandomized controlled trialEfficacy outcome
In healthy older adults, MK‑677 increased serum IGF-I from baseline at two weeks.
In plain wordsIn healthy older adults, serum IGF-I increased from baseline after two weeks of MK‑677.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF-I at two weeks
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg/day · oral · 2 weeksAs given in this study (human).
Measurements
IGF-I
141 microgram/L
baseline
IGF-I
219 micrograms/L
2 weeks
Reported +/- uncertainty of mean serum IGF-I (type not stated)
21 microgram/L
25 mg/day MK-677, baseline
Reported +/- uncertainty of mean serum IGF-I (type not stated)
21 micrograms/L
25 mg/day MK-677, 2 weeks
P value for serum IGF-I increase
< 0.05 unitless
25 mg/day MK-677, 2 weeks versus baseline
Source sentences
Summary
With 25 mg/day MK-677 treatment, mean serum IGF-I concentrations increased into the normal range for young adults (141 +/- 21 microgram/L at baseline, 219 +/- 21 micrograms/L at 2 weeks, and 265 +/- 29 micrograms/L at 4 weeks; P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial.
Summary · context
They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days.
Report a problemFND-0895402307
07HumanRandomized controlled trialEfficacy outcome
In healthy older adults, MK‑677 increased serum IGF-I from baseline at four weeks.
In plain wordsIn healthy older adults, serum IGF-I increased from baseline after four weeks of MK‑677.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF-I at four weeks
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25 mg/day · oral · 4 weeksAs given in this study (human).
Measurements
IGF-I
141 microgram/L
baseline
IGF-I
265 micrograms/L
4 weeks
Reported +/- uncertainty of mean serum IGF-I (type not stated)
21 microgram/L
25 mg/day MK-677, baseline
Reported +/- uncertainty of mean serum IGF-I (type not stated)
29 micrograms/L
25 mg/day MK-677, 4 weeks
P value for serum IGF-I increase
< 0.05 unitless
25 mg/day MK-677, 4 weeks versus baseline
Source sentences
Summary
With 25 mg/day MK-677 treatment, mean serum IGF-I concentrations increased into the normal range for young adults (141 +/- 21 microgram/L at baseline, 219 +/- 21 micrograms/L at 2 weeks, and 265 +/- 29 micrograms/L at 4 weeks; P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial.
Summary · context
They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days.
Report a problemFND-0895402308
08HumanRandomized controlled trialEfficacy outcome
In healthy older adults, MK‑677 increased fasting glucose versus baseline.
In plain wordsIn healthy older adults, fasting glucose increased from baseline with MK‑677.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseFasting glucose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 4 weeksAs given in this study (human).
Measurements
fasting glucose
5.4 mmol/L
baseline
fasting glucose
6.8 mmol/L
4 weeks
Reported +/- uncertainty of fasting glucose (type not stated)
0.3 mmol/L
baseline
Reported +/- uncertainty of fasting glucose (type not stated)
0.4 mmol/L
MK-677, 4 weeks
P value for fasting glucose increase
< 0.01 unitless
MK-677, 4 weeks versus baseline
Source sentences
Summary
MK-677 produced significant increases in fasting glucose (5.4 +/- 0.3 to 6.8 +/- 0.4 mmol/L at 4 weeks; P < 0.01 vs. baseline) and IGF-binding protein-3.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial.
Summary · context
They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days.
Report a problemFND-0895402309
09HumanRandomized controlled trialEfficacy outcome
In healthy older adults, MK‑677 increased IGF-binding protein-3.
In plain wordsIn healthy older adults, MK‑677 increased IGF-binding protein-3.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF-binding protein-3
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
MK-677 produced significant increases in fasting glucose (5.4 +/- 0.3 to 6.8 +/- 0.4 mmol/L at 4 weeks; P < 0.01 vs. baseline) and IGF-binding protein-3.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial.
Summary · context
They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days.
Report a problemFND-0895402310
10HumanRandomized controlled trialEfficacy outcome
In healthy older adults, circulating cortisol did not change with MK‑677.
In plain wordsIn healthy older adults, cortisol did not change with MK‑677.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeCortisol
Study
n: not reported in source
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
Circulating cortisol concentrations did not change, and PRL concentrations increased 23%, but remained within the normal range.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial.
Summary · context
They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days.
Report a problemFND-0895402311
11HumanRandomized controlled trialEfficacy outcome
In healthy older adults, PRL increased with MK‑677 but remained within the normal range.
In plain wordsIn healthy older adults, PRL increased with MK‑677 but remained within the normal range.
Peptide
MK-677 (ibutamoren)
Outcome
IncreasePRL
Study
n: not reported in source
Outcome group
Pituitary hormones · Endocrine and hormones
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
PRL increase
23%
MK-677 treatment
Source sentences
Summary
Circulating cortisol concentrations did not change, and PRL concentrations increased 23%, but remained within the normal range.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial.
Summary · context
They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days.
Report a problemFND-0895402312

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1/2NCT00474279

Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults

University of Virginian = 72Jul 1998 to Jun 2004

Aging

Trial page ClinicalTrials.govUpdated 16 May 2007

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.